Real-world experience with BVS: Trading early sacrifices for a (possible) brighter future.
Randomized clinical trial data suggest non-inferiority of bioresorbable vascular scaffolds (BVS) compared to current drug-eluting stent. Compared to randomized data, observational studies with BVS have revealed higher rates of scaffold thrombosis. Meticulous deployment technique of the device including appropriate vessel sizing, optimal scaffold apposition, and avoidance of overexpansion may likely limit the risk of scaffold thrombosis. Large randomized studies with longer follow-up are essential to define the role of this novel technology during routine clinical practice.